Abstract
The present study investigates the specific drug targeting of anti retroviral drugs, such as lamivudine and zidovudine, after intraperitoneal (i.p) injection by incorporation into polymeric nanoparticles (PNs) and solid lipid nanoparticles (SLNs). Our results showed that Glyceryl Monosterate-Poloxamer 188 SLNs (average diameter of 522.466 nm) showed slow drug release rates (63.18% of lamivudine and 62.37% of zidovudine were released in 12 hrs) among all the SLN formulations. For Poly lactic-co-glycolic acid (PLGA)-Poloxamer 188 PNs (average diameter of 70.348 nm), there were faster release rates of both lamivudine and zidovudine (97% and 94.06%, respectively, in 12 hrs). Tissue distribution studies were carried out in mice and concentrations of drugs in different organs were determined using high performance liquid chromatography (HPLC) after i.p. administration. Glyceryl Monosterate-Poloxamer 188 SLNs and PLGAPoloxamer 188 PNs showed increase in the distribution of lamivudine and zidovudine to liver and spleen when compared to the drugs in solution. Also, Glyceryl Monosterate-P 188 SLNs showed higher concentration of drugs in RES organs than PLGA-P 188 PNs.
Keywords: Drug targeting, high performance liquid chromatography, Lamivudine, Zidovudine, nanoparticles, transdermal absorption, electrically neutral polymer, physicochemical properties.
Current Drug Delivery
Title:Comparative Studies of Lamivudine-zidovudine Nanoparticles for the Selective Uptake by Macrophages
Volume: 9 Issue: 5
Author(s): V. Sankar, Parmar Nilaykumar Nareshkumar, Gohel Nishit Ajitkumar, Shalini Devi Penmetsa and Sivaram Hariharan
Affiliation:
Keywords: Drug targeting, high performance liquid chromatography, Lamivudine, Zidovudine, nanoparticles, transdermal absorption, electrically neutral polymer, physicochemical properties.
Abstract: The present study investigates the specific drug targeting of anti retroviral drugs, such as lamivudine and zidovudine, after intraperitoneal (i.p) injection by incorporation into polymeric nanoparticles (PNs) and solid lipid nanoparticles (SLNs). Our results showed that Glyceryl Monosterate-Poloxamer 188 SLNs (average diameter of 522.466 nm) showed slow drug release rates (63.18% of lamivudine and 62.37% of zidovudine were released in 12 hrs) among all the SLN formulations. For Poly lactic-co-glycolic acid (PLGA)-Poloxamer 188 PNs (average diameter of 70.348 nm), there were faster release rates of both lamivudine and zidovudine (97% and 94.06%, respectively, in 12 hrs). Tissue distribution studies were carried out in mice and concentrations of drugs in different organs were determined using high performance liquid chromatography (HPLC) after i.p. administration. Glyceryl Monosterate-Poloxamer 188 SLNs and PLGAPoloxamer 188 PNs showed increase in the distribution of lamivudine and zidovudine to liver and spleen when compared to the drugs in solution. Also, Glyceryl Monosterate-P 188 SLNs showed higher concentration of drugs in RES organs than PLGA-P 188 PNs.
Export Options
About this article
Cite this article as:
Sankar V., Nilaykumar Nareshkumar Parmar, Nishit Ajitkumar Gohel, Devi Penmetsa Shalini and Hariharan Sivaram, Comparative Studies of Lamivudine-zidovudine Nanoparticles for the Selective Uptake by Macrophages, Current Drug Delivery 2012; 9 (5) . https://dx.doi.org/10.2174/156720112802650707
DOI https://dx.doi.org/10.2174/156720112802650707 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research The Current Use of Mass Spectrometry in Combination with Other Separation Techniques in Drug Discovery Arena
Medicinal Chemistry Editorial (Thematic Issue: Global Clinical Trials, Research, Regulations and Education)
Applied Clinical Research, Clinical Trials and Regulatory Affairs The role of NADPH Oxidase in Vascular Disease – Hypertension, Atherosclerosis & Stroke
Current Pharmaceutical Design Prevalence of Diabetes Ketoacidosis Rises and Still No Strict Treatment Adherence
Current Diabetes Reviews Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Relationship Between Oxidative Stress, Tau Level and Antioxidant Mechanisms of the KEAP-1/NRF-2/HO-1 in Children with Hydrocephalus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice
Current Hypertension Reviews The Impact of Infection on the Incidence of Autoimmune Disease
Current Topics in Medicinal Chemistry Pharmacokinetics of Topical Ocular Drug Delivery: Potential Uses for the Treatment of Diseases of the Posterior Segment and Beyond
Current Drug Metabolism The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Pathogenesis-Oriented Targets for Adjunctive Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: “An Overview on Proteins of Biomedical Importance in Targeted Therapy of Cancer, Duchenne Muscular Dystrophy and Protein Misfolding Associated Neuropathy: Structure Function Relationship, Mechanism of Action, Role of Small Molecule Antagonist and Future Perspective”)
Current Chemical Biology Preparation and Characterization of Solid Lipid Nanoparticles-A Review
Current Drug Discovery Technologies An Insight into the Therapeutic Potential of Major Coffee Components
Current Drug Metabolism Blockade of Chemokine-Mediated Tissue Injury in Lupus Nephritis
Endocrine, Metabolic & Immune Disorders - Drug Targets Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets Potential of Gene Therapy for the Treatment of Pituitary Tumors
Current Gene Therapy Flaxseed and Diabetes
Current Pharmaceutical Design